Takeda extends reach into vaccines with HPV deal
This article was originally published in Scrip
Takeda has moved further into the vaccines sector with the licensing of exclusive global rights for the use of a patent for a human papillomavirus (HPV) vaccine held by the Japan Health Sciences Foundation (JHSF).
You may also be interested in...
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.
Reimbursement issues continued to dominate the policy sphere in Japan during the last decade, while new forms of therapy benefited from positive regulatory reforms. Meanwhile, consolidation and specialization were major threads running through the corporate sector.
Spreading China outbreak not a point of focus for companies or analysts in quarterly results briefings.